

# Mortality of Drug-resistant Tuberculosis in High-burden Countries: Comparison of Routine Drug Susceptibility Testing with Whole-genome Sequencing

Martina L. Reichmuth,<sup>a\*</sup> Kathrin Zürcher,<sup>a\*</sup> Marie Ballif,<sup>a</sup> Chloé Loiseau,<sup>b,c</sup> Sonia Borrell,<sup>b,c</sup> Miriam Reihnhard,<sup>b,c</sup> Veronika Skrivankova,<sup>a</sup> Rico Hömke,<sup>d,e</sup> Peter Sander,<sup>d,e</sup> Anchalee Avihingsanon,<sup>f</sup> Alash'le G Abimiku,<sup>g</sup> Olivier Marcy,<sup>h</sup> Jimena Collantes,<sup>i</sup> E. Jane Carter,<sup>j,k</sup> Robert J. Wilkinson,<sup>l,m,n</sup> Helen Cox,<sup>l,o</sup> Marcel Yotebieng,<sup>p,q</sup> Robin Huebner,<sup>r</sup> Lukas Fenner,<sup>a</sup> Erik C. Böttger,<sup>d,e</sup> Sebastien Gagneux,<sup>b,c</sup> Matthias Egger,<sup>a,s</sup> on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA)

\*contributed equally

- a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- b) Swiss Tropical and Public Health Institute, Basel, Switzerland
- c) University of Basel, Basel, Switzerland
- d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
- e) Swiss National Center for Mycobacteria, Zurich, Switzerland
- f) The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis research unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- g) Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria
- h) Centre de Prise en Charge de Recherche et de Formation, Yopougon, Abidjan, Côte d'Ivoire
- i) Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
- j) Department of Medicine, Moi University School of Medicine, and Moi Teaching and Referral Hospital, Eldoret, Kenya
- k) Brown University School of Medicine, Providence, Rhode Island, USA
- l) Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Republic of South Africa
- m) Department of Infectious Diseases, Imperial College, London, UK
- n) The Francis Crick Institute, London, UK
- o) Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa
- p) National TB Lab, Kinshasa, Democratic Republic of the Congo (DRC)
- q) Albert Einstein College of Medicine, New York, USA
- r) National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- s) Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, Republic of South Africa

**Correspondence to:** Marie Ballif, [marie.ballif@ispm.unibe.ch](mailto:marie.ballif@ispm.unibe.ch), +41 31 631 35 18, Institute of Social and Preventive Medicine, University Bern, Mittelstrasse 43, 3012 Bern, Switzerland

**Word count:** Abstract 350 words, main text 3260 words, 3 tables, 3 figures, 30 references, supplementary materials.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 51 Abstract

52

53 **Background:** Drug-resistant *Mycobacterium tuberculosis* (*Mtb*) strains threaten tuberculosis (TB)  
54 control. We compared data on drug resistance obtained at clinics in seven high TB burden countries  
55 during routine care with whole-genome sequencing (WGS) carried out centrally.

56 **Methods:** We collected pulmonary *Mtb* isolates and clinical data from adult TB patients in Africa, Latin  
57 America, and Asia, stratified by HIV status and drug resistance, from 2013 to 2016. Participating sites  
58 performed drug susceptibility testing (DST) locally, using routinely available methods. WGS was done  
59 using Illumina HiSeq 2500 at laboratories in the USA and Switzerland. We used TBprofiler to analyse  
60 the genomes. We used multivariable logistic regression adjusted for sex, age, HIV-status, history of TB,  
61 sputum positivity, and *Mtb*-lineage to analyse mortality.

62 **Findings:** We included 582 TB patients. The median age was 32 years (interquartile range: 27-43  
63 years), 225 (39%) were female, and 247 (42%) were HIV-positive. Based on WGS, 339 (58%) isolates  
64 were pan-susceptible, 35 (6%) mono-resistant, 146 (25%) multidrug-resistant, and 24 (4%) pre-/  
65 extensively drug-resistant (pre-XDR/XDR-TB). The local DST results were discordant compared to  
66 WGS results in 130/582 (22%) of patients. All testing methods identified isoniazid and rifampicin  
67 resistance with relatively high agreement (kappa 0.69 for isoniazid and 0.88 rifampicin). Resistance to  
68 ethambutol, pyrazinamide, and second-line drugs was rarely tested locally. Of 576 patients with known  
69 treatment, 86 (15%) patients received inadequate treatment according to WGS results and the World  
70 Health Organization treatment guidelines. The analysis of mortality was based on 530 patients; 63  
71 patients (12%) died and 77 patients (15%) received inadequate treatment. Mortality ranged from 6% in  
72 patients with pan-susceptible *Mtb* (18/310) to 39% in patients with pre-XDR/XDR-TB (9/23). The  
73 adjusted odds ratio for mortality was 4.82 (95% CI 2.43-9.44) for under-treatment and 0.52 (95% CI  
74 0.03-2.73) for over-treatment.

75 **Interpretation:** In seven high-burden TB countries, we observed discrepancies between drug  
76 resistance patterns from local DST and WGS, which resulted in inadequate treatment and higher  
77 mortality. WGS can provide accurate and detailed drug resistance information, which is required to  
78 improve the outcomes of drug-resistant TB in high burden settings. Our results support the WHO's call  
79 for point-of-care tests based on WGS.

80

81 **Keywords:** *Mycobacterium tuberculosis*, tuberculosis (TB), drug resistance, drug-susceptibility testing  
82 (DST), whole-genome sequencing (WGS), mortality

83

## 84 Introduction

85 Tuberculosis (TB) is caused by bacteria of the *Mycobacterium tuberculosis* complex (MTBC) and the  
86 leading cause of death by a single infectious agent worldwide. In 2018, ten million people were  
87 estimated to have developed active TB, of whom 9% were people living with HIV (PLWH). In the same  
88 year, around 1.5 million people died from TB, including 251,000 PLWH.<sup>1</sup> TB accounts for approximately  
89 40% of HIV/AIDS-related adult deaths, and half of these remain undiagnosed.<sup>2</sup>

90 The emergence of drug-resistant *Mycobacterium tuberculosis* (*Mtb*) strains threatens TB control. In  
91 2018, 3% of new TB cases worldwide were estimated to have multidrug-resistant TB (MDR-TB), and  
92 18% of previously treated cases had MDR-TB.<sup>1</sup> PLWH are at greater risk of acquiring MDR-TB than  
93 HIV-negative people.<sup>3</sup> Further, treatment outcomes in PLWH co-infected with MDR-TB are worse than  
94 among HIV-negative MDR-TB patients.<sup>3</sup> Pre-extensively and extensively drug-resistant TB (pre-XDR-  
95 TB and XDR-TB) pose additional challenges for treatment and control of the disease.<sup>4</sup> Strategies to  
96 control and prevent drug-resistant TB include surveillance, drug susceptibility testing (DST), as well as  
97 ensuring the completion of an adequate treatment regimen. However, the treatment of drug-resistant  
98 TB is challenging particularly in low- and middle-income countries, due to limited access to DST and  
99 effective second-line anti-TB drugs.<sup>1</sup>

100 The present study is part of a research program on drug-resistant TB of the International Epidemiology  
101 Databases to Evaluate AIDS (IeDEA).<sup>5</sup> In a previous analysis, we compared the results of drug  
102 susceptibility testing (DST) performed in high TB burden countries in sub-Saharan Africa, Asia and Latin  
103 America with standardized phenotypic DST results obtained at the Swiss National Center for  
104 Mycobacteria.<sup>6</sup> We found that the accuracy of the DST performed at participating sites was moderate  
105 and that inadequate DST was associated with increased mortality. The Swiss reference laboratory  
106 tested drug resistance to six drugs only: isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA),  
107 ethambutol (EMB), amikacin (AMK) and moxifloxacin (MFX). Therefore, other resistances could have  
108 been missed, including to streptomycin (SM), kanamycin (KM), ethionamide (ETH), levofloxacin (LFX),  
109 or newer drugs.

110 Whole-genome sequencing (WGS) can simultaneously provide information on resistance to first- and  
111 second-line drugs, for which drug-resistance-conferring mutations are known. WGS has the potential  
112 to overcome many of the limitations of conventional DST with higher throughput.<sup>7</sup> We and others  
113 showed that drug susceptibility predicted from *Mtb* genomes correlates with phenotypic DST.<sup>8,9</sup> The  
114 World Health Organization (WHO) recommends WGS for drug resistance surveillance and is evaluating  
115 sequencing technologies for routine DST.<sup>1</sup> Here, we compared the drug resistance patterns routinely  
116 obtained in seven high TB burden countries with the results from WGS, and examined the mortality  
117 associated with discordant resistance profiles using WGS as the reference.

118

## 119 Methods

120 As described in detail elsewhere,<sup>6</sup> we recruited patients from 2013 to 2016 at antiretroviral therapy  
121 (ART) programmes and TB clinics serving the same catchment areas in Peru, Thailand, Côte d'Ivoire,  
122 Democratic Republic of the Congo (DRC), Kenya, Nigeria, and South Africa. In South Africa, we used  
123 strain collections held at the University of Cape Town. All patients had bacteriologically confirmed, or  
124 clinically diagnosed TB. We included adult patients ( $\geq 16$  years) with pulmonary TB (PTB) or both PTB  
125 and extrapulmonary TB. The recruitment of patients was stratified by HIV status and TB drug resistance  
126 as defined at local clinics. We collected demographic and clinical characteristics of participants using a  
127 standardised questionnaire. *Mtb* isolates were sub-cultured at the recruitment sites.

### 128 Drug resistance testing

129 Molecular or phenotypic DST was performed at local laboratories according to routine procedures. DNA  
130 was extracted from *Mtb* isolates using standard protocols.<sup>10</sup> Libraries were prepared using the Illumina  
131 Nextera XT kit and sequenced on Illumina HiSeq 2500 at the Department of Biosystems Science and  
132 Engineering of the Swiss Federal Institute of Technology (ETHZ) in Basel and the Broad Institute in  
133 Cambridge, MA, USA. Sequences had 101, 138, or 151 bp paired-end reads (Illumina, San Diego, CA,  
134 USA). We screened one *Mtb* isolate per patient for anti-TB drug resistance mutations using the  
135 TBProfiler-v2.8.2 pipeline (<https://github.com/jodyphelan/TBProfiler>).<sup>7,11</sup> The pipeline aligns reads to the  
136 H37Rv reference genome using bowtie2-v2.3.5, BWA-v0.7.17 or minimap2-v2.16 and calls variants  
137 with SAMtools-v1.9.<sup>7,12-15</sup> The variants were then compared to a drug-resistance database  
138 (<https://github.com/jodyphelan/tbdb>; version of 30.01.2020). Single-nucleotide polymorphism (SNPs)  
139 and insertion-deletion (Indels) responsible for resistance to 19 anti-TB drugs were identified:<sup>7,11,16</sup> SM,  
140 para-aminosalicylic-acid (PAS), INH, PZA, cycloserine (CS), KM, ETH, EMB, AMK, RIF, capreomycin  
141 (CAP), ofloxacin (OFX), ciprofloxacin (CIP), MFX, LFX, linezolid (LZD), bedaquiline (BDQ), clofazimine  
142 (CFZ), and delamanid (DLM). A coverage of 10 reads was needed to call a polymorphism. We  
143 considered all drug resistance alleles with a variant frequency equal to or higher than 90%.

### 144 Definitions

145 WHO defines monoresistance as resistance to one of the first-line drugs (INH-, PZA-, EMB-, and  
146 RIF).<sup>1,17</sup> MDR-TB is defined as resistance to both INH and RIF. Pre-XDR-TB is defined as resistance  
147 against INH and RIF plus fluoroquinolones (FQLs) or one of the three second-line injectable (INJ) drugs  
148 (AMK, CAP, KM). Extensively drug-resistant TB (XDR-TB) is defined as drug-resistance against INH,  
149 RIF, FQLs and at least one of the three second-line INJ drugs.

150 We compared the drug resistance profiles obtained at local sites to those obtained with WGS. Drug  
151 resistance profiles were defined as concordant or as discordant according to the resistance categories  
152 defined by WHO.<sup>1</sup> Discordant results were further categorized into discordant results potentially leading  
153 to under-treatment, or potentially leading to over-treatment ([Supplementary Table 1](#)).<sup>1,17</sup> Discordances  
154 with no clear implications for treatment were defined as "other discordances". We assessed the  
155 adequacy of prescribed anti-TB treatment according to WHO guidelines ([Supplementary Table 1](#)).<sup>1,17</sup>  
156 Effective drugs were defined as drugs to which *Mtb* strains had no drug resistance-conferring mutations

157 observed in whole-genome sequences ([Supplementary Table 2](#)). The prescription of less than three  
158 effective drugs was defined as under-treatment, except for patients with INH- or RIF-resistant *Mtb*. In  
159 these patients, a regimen comprising less than four effective drugs was already considered as under-  
160 treatment. Over-treatment included second-line drugs given to patients for whom first-line regimens  
161 would have been adequate. [Supplementary Table 3](#) shows the classification of regimens in detail.

## 162 [Statistical methods](#)

163 We used descriptive statistics to assess patient characteristics by levels of drug resistance based on  
164 WGS. We calculated the agreement between the results of local and WGS drug resistance results using  
165 Cohen's Kappa statistic (in R package "psych").<sup>18,19</sup> We compared the following drug resistance  
166 categories: pan-susceptible TB, monoresistant TB (any monoresistance), MDR-TB, pre-XDR/XDR-TB,  
167 any INH-resistant TB (including INH-monoresistant TB, MDR-TB and pre-XDR/XDR-TB), any RIF-  
168 resistant TB (including RIF-monoresistant TB, MDR-TB and pre-XDR/XDR-TB). We examined the  
169 determinants of mortality in univariable and multivariable logistic regression models. Patients with  
170 missing data on treatment regimen, treatment outcome, ongoing treatment, and sputum microscopy,  
171 respectively, were excluded from the analysis of mortality.

172 Four separate logistic regression models were performed to assess the impact on mortality: 1) the  
173 impact of any drug resistance on mortality, 2) the impact of different types of drug resistance on  
174 mortality, 3) the impact of discordant diagnoses on mortality, and 4) the impact of treatment adequacy  
175 (according to WHO guidelines) on mortality. Logistic regression models were adjusted for sex, age,  
176 HIV-status, history of TB, sputum positivity, and *Mtb* lineage ([Supplementary Table 4](#)). All analyses  
177 were performed in R v3.6.1 or Python v3.7.6.<sup>18,20</sup> We conducted two sensitivity analyses. First, we  
178 repeated all logistic regression analyses after restricting the data to drug resistances that could be  
179 diagnosed with the locally available tests. We thus excluded drug resistances that were missed due to  
180 unavailable testing methods. Second, we examined the impact of different variant frequency cut-offs: >  
181 0% and 100%.

## 182 [Ethics](#)

183 The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards approved  
184 the study. Written informed consent was obtained at all sites, except in South Africa, where consent  
185 was not required for archived samples.

186

## 187 Results

### 188 Study population

189 Of the 634 patients included in our previous analysis,<sup>6</sup> we failed to sequence 52 (8.2%) *Mtb* isolates for  
190 technical reasons ([Supplementary Figure 1](#)). We thus included 582 TB patients, 406 (70%) from Africa,  
191 83 (14%) from Asia, and 93 (16%) from Latin America. A total of 172 patients (30%) came from South  
192 Africa, 94 (16%) from Côte d'Ivoire, 59 (10%) from the Democratic Republic of the Congo, 28 (5%) from  
193 Kenya, 53 (9%) from Nigeria, 93 (16%) from Peru, and 83 (14%) from Thailand ([Table 1](#)). The median  
194 age was 32 years (interquartile range: 27-43 years), 225 (39%) were female, and 247 (42%) were HIV-  
195 positive. Six *Mtb* lineages were represented: 24 (4%) L1, 135 (23%) L2, 18 (3%) L3, 403 (69%) L4, one  
196 (<1%) L5, and one (<1%) L6. Based on WGS, 339 (58%) isolates were pan-susceptible, 35 (6%)  
197 mono-resistant, including 24 (4%) RIF, 8 (1%) INH, 2 (<1%) PZA and 1 (<1%) EMB mono-resistant  
198 isolates. There were 146 (25%) MDR, and 24 (4%) pre-XDR/XDR isolates ([Table 1](#); [Figure 1](#)). Among  
199 the 24 patients with pre-XDR/XDR, 9/24 (38%) had resistance to FQLs, 6 (25%) to INJ, and 9 (38%) to  
200 both.

### 201 Local results of DST

202 Local DST results were based on the molecular Xpert MTB/RIF test system, line probe assays (LPA),  
203 and culture-based phenotypic tests or a combination of these methods ([Table 2](#)). Among the 582 *Mtb*  
204 isolates, 130/582 (22%) had discordant drug resistance results that potentially led to inadequate  
205 treatments in 66/582 (11%) of TB patients ([Table 2](#)). In 35/50 (70%) patients, under-diagnosis  
206 potentially led to under-treatment, and in 31/80 (39%), over-diagnosis potentially led to over-treatment  
207 ([Table 2](#)). For six patients, we had no treatment information. Of 576 patients with known treatment, we  
208 observed that overall, 86/576 (15%) patients received inadequate treatment according to WGS results  
209 and WHO treatment guidelines: 67/576 (12%) patients were under-treated, and 19 (3%) were over-  
210 treated. Consequently, 490/576 (85%) were adequately treated.

211 The agreement between local DST and WGS (as assessed by Cohen's kappa) were 0.74 (95% CI 0.69-  
212 0.8) for pan-susceptible, 0.09 (-0.03-0.2) for mono-resistant, 0.71 (0.65-0.77) for MDR, and 0.49 (0.28-  
213 0.69) for pre-XDR/XDR-TB cases ([Figure 1](#)). Agreement of local DST and WGS for RIF resistance were  
214 0.88 (0.84-0.92) and 0.69 (0.63-0.76) for INH resistance ([Figure 1](#)). RIF resistance was, in contrast to  
215 other drug resistance, more frequently diagnosed with local DST than with WGS ([Figure 1](#)). Only three  
216 sites tested other drugs than RIF and INH. Two sites tested for SM, two for FQLs, and two for INJ. One  
217 site tested for PZA and one site for EMB. Resistance to PAS, CS, EMB, LZD, BDQ, CFZ, and DLM was  
218 not tested at any site. Resistance to the latter three was also not diagnosed with WGS using a threshold  
219 of  $\geq 90\%$  variant frequency ([Supplementary Table 5](#)).

### 220 Mortality

221 We excluded 52/582 (9%) patients due to missing data ([Table 1](#); [Supplementary Figure 1](#)). The included  
222 patients' median age was 34 years (interquartile range: 27-43 years), 207 (39%) were female, and 218  
223 (41%) were HIV-positive. Based on WGS, the *Mtb* isolates of 310 (58%) patients were pan-susceptible,  
224 32 (6%) mono-resistant, 131 (25%) MDR and 23 (4%) pre-XDR/XDR. Among the 530 isolates, 121  
225 (23%) had a discordant diagnosis. For 30/44 (68%) patients, the under-diagnosis of drug resistance

226 potentially led to under-treatment, and for 28/77 (36%) the over-diagnosis potentially led to over-  
227 treatment.

228 During treatment, 63/530 (12%) patients died ([Table 3](#)). Patients with pan-susceptible *Mtb* had a  
229 mortality of 18/310 (6%), patients with mono-resistant TB had a mortality of 6/32 (19%), patients with  
230 MDR-TB had a mortality of 24/131 (18%), and patients with pre-XDR/XDR-TB had a mortality of 9/23  
231 (39%) ([Figure 2A](#)). Overall, mortality ranged from 16/267 (6%) among patients with pan-susceptible  
232 strains and concordant diagnosis to 7/15 (47%) among patients with pre-XDR/XDR-TB and a discordant  
233 diagnosis potentially leading to under-treatment ([Table 3](#)). In patients with a discordant diagnosis  
234 potentially leading to under-treatment, mortality was 8/30 (27%), and in patients with discordant  
235 diagnosis potentially leading to over-treatment, it was 1/28 (4%) ([Figure 2B](#)). Mortality ranged from  
236 17/293 (6%) in patients with pan-susceptible TB treated according to WHO guidelines to 19/60 (32%)  
237 in under-treated patients and 1/17 (6%) in patients who were over-treated ([Figure 2C](#)).

238 In the multivariable logistic regression adjusted for sex, age, HIV status, history of TB, sputum  
239 microscopy, and TB lineage, resistance to any of the anti-TB drugs was associated with higher mortality  
240 ([Figure 3](#); [Supplementary Table 4](#)): the adjusted odds ratio (aOR) was 5.71 (95% CI 3.02-11.25). The  
241 association with mortality became stronger with higher degree of drug resistance. Compared to pan-  
242 susceptible TB, the odds ratios for mono-resistant, MDR-, and pre-XDR/XDR TB were 5.40 (95% CI  
243 1.73-15.49), 5.76 (95% CI 2.71-12.54), and 22.07 (95% CI 7.21-68.27), respectively ([Figure 3](#)). The  
244 aOR for mortality during TB treatment was 3.82 (95% CI 1.47-9.25) in patients with a diagnosis  
245 potentially leading to under-treatment, and 0.28 (95% CI 0.02-1.39) in the case of a diagnosis potentially  
246 leading to over-treatment, compared to patients with concordant treatment ([Figure 3](#)). Overall, 77/530  
247 (15%) patients received inadequate treatment based on WGS drug resistance results and WHO  
248 guidelines ([Supplementary Table 3](#)): 60/530 (11%) patients were under-treated, and 17/530 (3%) were  
249 over-treated. The odds ratio for mortality for under-treatment was 4.82 (95% CI 2.43-9.44), and for over-  
250 treatment, it was 0.52 (95% CI 0.03-2.73), compared to patients receiving adequate treatment ([Figure](#)  
251 [3](#)).

252 The sensitivity analysis using different variant frequency cut-offs (> 0% and 100%) produced similar  
253 results ([Supplementary Figure 2 and 3](#)). When restricting the analysis to drug resistances which could  
254 be diagnosed at sites, again similar results were obtained ([Supplementary Figure 4](#)).

## 255 Discussion

256

257 Drug-resistant TB is a significant global health problem. In this multicentre cohort study of 582 TB  
258 patients, we compared drug resistance predicted by WGS with the results from local DST in eight high-  
259 burden TB countries. We examined mortality by drug resistance predicted by WGS, and by  
260 concordance or discordance with local diagnosis and treatment. We found that the diagnosis was  
261 discordant between local drug resistance results and WGS in about one in five patients. The agreement  
262 between local and centralized WGS was the highest for RIF and INH but low for other drugs. Of note,  
263 resistance to SM, PAS, PZA, CS, ETH, EMB, FQLs, and INJ was rarely investigated locally. Mortality  
264 during treatment ranged from 6% among patients with pan-susceptible strains and concordant results  
265 between WGS and local drug resistance testing to 47% among patients with pre-XDR/XDR TB and  
266 discordant results.

267 To our knowledge, this is the first study to compare the results from DST in real-world settings in high-  
268 burden countries with WGS and to examine the impact of discordant resistance results on mortality. In  
269 a previous study of this cohort, we compared the results from local DST with standardized liquid culture  
270 on six drugs performed at the Swiss National Center for Mycobacteria.<sup>6</sup> In the present study, we used  
271 a well-established bioinformatics pipeline and its corresponding database to analyse the WGS data.<sup>7</sup>  
272 The analysis covered 19 drugs, including SM, KM, PZA, ETH, EMB, LFX, and newer drugs. Specifically,  
273 we were able to detect more single drug resistance with WGS compared to phenotypic DST.

274 Rapid and accurate diagnosis, prompt and appropriate treatment, and the control of airborne infection  
275 are key strategies to prevent drug-resistant TB.<sup>21</sup> WGS has the potential to predict resistance profiles  
276 for most anti-TB drugs without the need for time-consuming phenotypic DST.<sup>1,7,8,16</sup> WGS allows  
277 effective individualised treatment and thus reduces the risk of propagating drug resistance. Ineffective  
278 treatment may lead to the acquisition of additional drug resistance and increased transmission of drug-  
279 resistant strains.<sup>21</sup> These considerations support the use of WGS to replace the current DST methods,  
280 which cover only a limited number of drugs. Culture-based DST is challenging for several drugs, for  
281 example, PZA, ETH, and EMB, due to poor drug solubility.<sup>8,22</sup> The accurate diagnosis of pertinent drug  
282 resistance is essential. For example, PZA is critical to shortening TB therapy, and resistance is related  
283 to a worse outcome.<sup>21</sup> Yet, PZA resistance testing is often unavailable. Only one site could test PZA  
284 resistance. Routine DST at sites focused mainly on the identification of RIF and INH resistance, used  
285 to defined MDR-TB, leaving the efficacy of other drugs unanswered. Furthermore, INH monoresistance  
286 would typically be missed when DST relies on the use of Xpert MTB/RIF, which could lead to the under-  
287 treatment of Xpert-negative individuals. In contrast to other molecular and phenotypic DST methods,  
288 WGS simultaneously detects all known drug resistance-conferring mutations. The wider range of drug  
289 resistance captured by WGS explains some of the discordant results found in this study. However,  
290 discordant results potentially leading to inadequate treatment were mainly due to drug resistance that  
291 was undiagnosed, despite the availability of tests at sites, rather than to a wider range of drug  
292 resistances captured by WGS.



293 The detection of drug resistance is influenced by the type of sample collected, and the methods used  
294 for culturing, DNA extraction and sequencing, and the pipeline used to analyse the sequences.<sup>23</sup> The  
295 latter was determined by a  $\geq 90\%$  variant frequency cut-off and the robustness of the TBprofiler pipeline  
296 and its coverage of all relevant resistance-conferring mutations. Our sensitivity analysis showed that  
297 the cut-off for variant frequency had little impact on results. For new drugs, most resistance-conferring  
298 mutations are unknown at the time of introduction, and relevant drug resistance mechanisms become  
299 apparent only later on. Discrepancies in results between local DST and WGS might be explained by  
300 mixed infections, heteroresistance, minority resistant populations, or methodological differences,<sup>23-25</sup>  
301 and lead to uncertainties in treatment decisions.<sup>26</sup> Of note, over-treatment did not increase mortality,  
302 but the analysis was based on few patients and should be interpreted with caution. Anti-TB drugs can  
303 have serious side effects, which may lead to treatment interruption and failure, or acquired drug  
304 resistance. Over-treatment should be avoided from both a medical and cost perspective.

305 Our study has several limitations. We sampled eligible patients within strata defined by drug resistance  
306 and HIV infection and therefore, could not estimate the incidence or prevalence of drug-resistant TB in  
307 HIV-positive or HIV-negative patients. We could also not evaluate differences in drug resistance  
308 between *Mtb* lineages, because the sample size was small for several lineages. Further, we sequenced  
309 *Mtb* strains before treatment and could thus not diagnose potential acquired drug resistance, which may  
310 influence treatment outcome. Finally, we started this study in 2013. Since then, TB treatment guidelines  
311 changed. In 2013, WHO published an interim policy guideline on BDQ and in 2014 on DLM in the  
312 treatment of MDR-TB.<sup>27,28</sup> In our study, patients were rarely treated with new drugs. Consequently, our  
313 results may not reflect the situation in 2020. However, our study does show that treatment strategies  
314 guided by comprehensive drug resistance data are likely to save lives.

315 Our results support WHO's call for an accurate point-of-care test based on WGS that can be performed  
316 directly from sputum samples.<sup>29</sup> Such tests would allow rapid diagnosis and efficient, individual-based  
317 treatment of drug-resistant TB. Test systems performing WGS on sputum samples and bioinformatics  
318 pipelines are currently in development. High-burden countries should consider building central, high-  
319 throughput sequencing capacities. The establishment of a trustworthy, widely accepted drug resistance  
320 database similar to the Stanford HIV drug resistance database will be essential in this context.<sup>30</sup> Finally,  
321 we support the call for clinical trials evaluating the efficacy, safety, tolerability of new TB treatment and  
322 DST strategies for drug-resistant TB.<sup>21</sup> Especially, the role of new drugs like BDQ, DLM, and pretomanid  
323 in regimens with fewer, more effective and safer drugs needs to be evaluated.<sup>21</sup> Future studies should  
324 also examine treatment duration and adherence.<sup>21</sup> The duration of the intensive and continuation  
325 phases of TB treatment and treatment adherence are crucial for efficient therapy.

326 In conclusion, our study shows that both the accuracy of DST in routine care and the access to testing  
327 for resistance for several essential drugs is limited in high-burden TB countries and that this leads to  
328 inadequate treatment and contributes to higher mortality. Our results support the role of WGS to  
329 improve the management of drug-resistant TB in high-burden TB settings.

330 **Data availability**

331 WGS data from patients *Mtb* strains included in this analysis have been submitted to the NCBI  
332 (PRJNA300846; [Supplementary Table 6](#)).

333 **Acknowledgement**

334 We thank all sites that participated, patients whose data were used in this study. We are also grateful  
335 to the Tuberculosis Working Group of leDEA for helpful discussions. This research was supported by  
336 the Swiss National Foundation (project grant numbers 153442, 310030\_188888, IZRJZ3\_164171,  
337 IZLSZ3\_170834, CRSII5\_177163 and special project grant 17481). The International Epidemiology  
338 Databases to Evaluate AIDS (leDEA) is supported by the US National Institutes of Health, National  
339 Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child  
340 Health and Human Development, the National Cancer Institute, the National Institute of Mental Health,  
341 the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute  
342 on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney  
343 Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific,  
344 U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911;  
345 NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919. RJW  
346 receives support from the Francis Crick Institute, which is funded by UKRI, CRUK (FC0010218), and  
347 Wellcome (104803, 203135). This work is solely the responsibility of the authors and does not  
348 necessarily represent the official views of any of the institutions mentioned above. Calculations were  
349 performed on UBELIX (<http://www.id.unibe.ch/hpc>), the HPC cluster at the University of Bern.

350

## 351 References

- 352 1. WHO. Global tuberculosis report 2019. World Health Organization Document 2019: 1-297.
- 353 2. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies  
354 of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis.  
355 *AIDS* 2015.
- 356 3. Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-  
357 drug resistance tuberculosis: a systematic review and meta-analysis. *PloS one* 2014; **9**(1): e82235.
- 358 4. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant  
359 tuberculosis: a threat to global control of tuberculosis. *Lancet* 2010; **375**(9728): 1830-43.
- 360 5. Antiretroviral Therapy in Low-Income Countries Collaboration of the International  
361 epidemiological Databases to Evaluate A, Collaboration ARTC, Brinkhof MW, et al. Tuberculosis after  
362 initiation of antiretroviral therapy in low-income and high-income countries. *Clin Infect Dis* 2007; **45**(11):  
363 1518-21.
- 364 6. Zürcher K, Ballif M, Fenner L, et al. Drug susceptibility testing and mortality in patients treated  
365 for tuberculosis in high-burden countries: a multicentre cohort study. *The Lancet Infectious Diseases*  
366 2019; **19**(3): 298-307.
- 367 7. Phelan JE, O'Sullivan DM, Machado D, et al. Integrating informatics tools and portable  
368 sequencing technology for rapid detection of resistance to anti-tuberculous drugs. *Genome Med* 2019;  
369 **11**(1): 41.
- 370 8. Gygli SM, Keller PM, Ballif M, et al. Whole-Genome Sequencing for Drug Resistance Profile  
371 Prediction in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2019; **63**(4).
- 372 9. Consortium CR, the GP, Allix-Beguec C, et al. Prediction of Susceptibility to First-Line  
373 Tuberculosis Drugs by DNA Sequencing. *N Engl J Med* 2018; **379**(15): 1403-15.
- 374 10. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of *Mycobacterium*  
375 tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. *J Clin Microbiol*  
376 1993; **31**(2): 406-9.
- 377 11. Coll F, Phelan J, Hill-Cawthorne GA, et al. Genome-wide analysis of multi- and extensively  
378 drug-resistant *Mycobacterium tuberculosis*. *Nat Genet* 2018; **50**(2): 307-16.
- 379 12. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of *Mycobacterium tuberculosis*  
380 from the complete genome sequence. *Nature* 1998; **393**(6685): 537-44.
- 381 13. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 2012; **9**(4):  
382 357-9.
- 383 14. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.  
384 *Bioinformatics* 2009; **25**(14): 1754-60.
- 385 15. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools.  
386 *Bioinformatics* 2009; **25**(16): 2078-9.
- 387 16. Coll F, McNerney R, Preston MD, et al. Rapid determination of anti-tuberculosis drug resistance  
388 from whole-genome sequences. *Genome Med* 2015; **7**(1): 51.

- 389 17. WHO. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health  
390 Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
- 391 18. Team RC. R: A language and environment for statistical computing. In: Computing RfS, editor.  
392 Vienna, Austria 2019.
- 393 19. Cohen J. A Coefficient of Agreement for Nominal Scales. *Educational and Psychological*  
394 *Measurement* 2016; **20**(1): 37-46.
- 395 20. Team PC. Python: A dynamic, open source programming language. Python Software  
396 Foundation; 2019.
- 397 21. Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official  
398 ATS/CDC/ERS/IDSA Clinical Practice Guideline. *Am J Respir Crit Care Med* 2019; **200**(10): e93-e142.
- 399 22. Dominguez J, Boettger EC, Cirillo D, et al. Clinical implications of molecular drug resistance  
400 testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. *Int J Tuberc Lung*  
401 *Dis* 2016; **20**(1): 24-42.
- 402 23. Metcalfe JZ, Streicher E, Theron G, et al. Mycobacterium tuberculosis Subculture Results in  
403 Loss of Potentially Clinically Relevant Heteroresistance. *Antimicrob Agents Chemother* 2017; **61**(11).
- 404 24. Cohen T, van Helden PD, Wilson D, et al. Mixed-strain mycobacterium tuberculosis infections  
405 and the implications for tuberculosis treatment and control. *Clin Microbiol Rev* 2012; **25**(4): 708-19.
- 406 25. Streicher EM, Bergval I, Dheda K, et al. Mycobacterium tuberculosis population structure  
407 determines the outcome of genetics-based second-line drug resistance testing. *Antimicrob Agents*  
408 *Chemother* 2012; **56**(5): 2420-7.
- 409 26. Hofmann-Thiel S, Hoffmann H, Hillemann D, Rigouts L, Van Deun A, Kranzer K. How should  
410 discordance between molecular and growth-based assays for rifampicin resistance be investigated? *Int*  
411 *J Tuberc Lung Dis* 2017; **21**(7): 721-6.
- 412 27. WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy  
413 guidance. Geneva: World Health Organization; 2013. (WHO/HTM/TB/2013.6).
- 414 28. WHO. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Geneva: World  
415 Health Organization; 2014 (WHO/HTM/TB2014.23).
- 416 29. WHO. The use of next-generation sequencing technologies for the detection of mutations  
417 associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva:  
418 World Health Organization; 2018 (WHO/CDS/TB/2018.19). Licence: CC BY-NC-SA 3.0 IGO.
- 419 30. Shafer RW. Rationale and uses of a public HIV drug-resistance database. *J Infect Dis* 2006;  
420 **194** Suppl 1: S51-8.

421

422 **Table 1. Patient characteristics by resistance profiles obtained by whole-genome sequencing.**

Factor	Pan-susceptible	Any resistance	p-value*	Mono-resistance	INH	PZA	EMB	RIF	Poly-resistance	MDR	pre-/XDR	others
	339	243	≤0.0001	35	8	2	1	24	208	146	24	38
<b>Gender</b>												
<i>Women</i>	131 (39%)	94 (39%)	≤0.05	10 (29%)	3 (38%)	0 (0%)	1 (100%)	6 (25%)	84 (40%)	56 (38%)	13 (54%)	15 (39%)
<i>Men</i>	208 (61%)	149 (61%)	≤0.01	25 (71%)	5 (62%)	2 (100%)	0 (0%)	18 (75%)	124 (60%)	90 (62%)	11 (46%)	23 (61%)
<b>Age</b>												
<i>At diagnosis (IQR)</i>	35 [28, 45]	32 [25, 40]	0.75	32 [25, 40]	40 [31.25, 48.5]	26 [24.5, 27.5]	36 [36, 36]	29 [24.75, 38.5]	32 [25.75, 40.25]	31 [25, 39]	29.5 [24.75, 34.25]	36 [29.25, 43.75]
<b>HIV status</b>												
<i>HIV-negative</i>	169 (50%)	166 (68%)	0.87	23 (66%)	7 (88%)	1 (50%)	0 (0%)	15 (62%)	143 (69%)	103 (71%)	14 (58%)	26 (68%)
<i>HIV-positive</i>	170 (50%)	77 (32%)	≤0.0001	12 (34%)	1 (12%)	1 (50%)	1 (100%)	9 (38%)	65 (31%)	43 (29%)	10 (42%)	12 (32%)
<b>Mtb Lineage</b>												
<i>L1</i>	18 (5%)	6 (2%)	≤0.05	2 (6%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)	4 (2%)	1 (1%)	0 (0%)	3 (1%)
<i>L2</i>	79 (23%)	56 (17%)	≤0.05	7 (20%)	3 (38%)	1 (50%)	0 (0%)	3 (12%)	49 (13%)	23 (16%)	8 (Inf%)	18 (47%)
<i>L3</i>	15 (4%)	3 (1%)	≤0.01	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)	2 (1%)	1 (4%)	0 (0%)
<i>L4</i>	225 (66%)	178 (66%)	≤0.05	26 (74%)	5 (62%)	1 (50%)	1 (100%)	19 (79%)	152 (73%)	120 (82%)	15 (62%)	17 (45%)
<i>L5</i>	1 (<1%)	0 (0%)	0.32	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<i>L6</i>	1 (<1%)	0 (0%)	0.32	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<b>Country</b>												
<i>Côte d'Ivoire</i>	46 (14%)	48 (20%)	0.84	5 (14%)	2 (25%)	0 (0%)	1 (100%)	2 (8%)	43 (21%)	39 (27%)	3 (12%)	1 (3%)
<i>Democratic Republic of the Congo</i>	29 (9%)	30 (12%)	0.9	1 (3%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	29 (14%)	19 (13%)	8 (33%)	2 (5%)
<i>Kenya</i>	21 (6%)	7 (6%)	≤0.01	1 (3%)	1 (12%)	0 (0%)	0 (0%)	0 (0%)	6 (3%)	5 (3%)	0 (0%)	1 (3%)
<i>Nigeria</i>	19 (6%)	34 (14%)	≤0.05	6 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (25%)	28 (13%)	20 (14%)	4 (17%)	4 (11%)
<i>South Africa</i>	111 (33%)	61 (25%)	≤0.001	15 (43%)	0 (0%)	1 (50%)	0 (0%)	14 (58%)	46 (22%)	28 (19%)	7 (29%)	11 (29%)
<i>Peru</i>	57 (17%)	36 (15%)	≤0.05	2 (6%)	2 (25%)	0 (0%)	0 (0%)	0 (0%)	34 (16%)	28 (19%)	2 (8%)	4 (11%)
<i>Thailand</i>	56 (17%)	27 (116%)	≤0.01	5 (14%)	3 (38%)	1 (50%)	0 (0%)	1 (4%)	22 (11%)	7 (5%)	0 (0%)	15 (39%)
<b>History of TB</b>												
<i>No</i>	269 (79%)	104 (43%)	≤0.0001	13 (37%)	7 (88%)	1 (50%)	1 (100%)	4 (17%)	91 (44%)	56 (38%)	5 (21%)	30 (79%)

Yes	70 (21%)	139 (79%)	≤0.0001	22 (63%)	1 (12%)	1 (50%)	0 (0%)	20 (83%)	117 (56%)	90 (62%)	19 (79%)	8 (21%)
<b>Treatment success</b>												
<i>Cured</i>	189 (56%)	83 (78%)	≤0.0001	10 (29%)	3 (38%)	0 (0%)	1 (100%)	6 (25%)	73 (35%)	45 (31%)	8 (33%)	20 (53%)
<i>Completed</i>	59 (17%)	46 (19%)	0.2	6 (17%)	2 (25%)	0 (0%)	0 (0%)	4 (17%)	40 (19%)	31 (21%)	3 (12%)	6 (16%)
<i>Died</i>	19 (6%)	45 (19%)	≤0.01	6 (17%)	1 (12%)	1 (50%)	0 (0%)	4 (17%)	39 (19%)	24 (16%)	9 (38%)	6 (16%)
<i>Treatment failure</i>	11 (3%)	10 (4%)	0.83	3 (9%)	0 (0%)	1 (50%)	0 (0%)	2 (8%)	7 (3%)	5 (3%)	2 (8%)	0 (0%)
<i>Defaulted</i>	20 (6%)	22 (9%)	0.76	0 (9%)	0 (0%)	0 (0%)	0 (0%)	3 (12%)	19 (9%)	17 (12%)	0 (0%)	2 (5%)
<i>Lost to follow up</i>	6 (2%)	7 (3%)	0.78	2 (6%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)	5 (2%)	5 (3%)	0 (0%)	0 (0%)
<i>Ongoing, unknown</i>	22 (6%)	15 (6%)	0.25	3 (97%)	2 (25%)	0 (0%)	0 (0%)	1 (4%)	12 (6%)	9 (6%)	0 (0%)	3 (8%)
<b>Sputum</b>												
<i>Positive</i>	264 (80%)	205 (85%)	≤0.01	25 (71%)	7 (88%)	1 (50%)	1 (100%)	16 (67%)	180 (87%)	129 (88%)	17 (74%)	34 (92%)
<i>Negative</i>	68 (20%)	36 (15%)	≤0.01	10 (29%)	1 (12%)	1 (50%)	0 (0%)	8 (33%)	26 (13%)	17 (12%)	6 (26%)	3 (8%)

423

424 P-value\*, difference between pan-susceptible and any resistance with chi-square test. The category others includes following drug resistance: CS; EMB,RIF;  
425 ETH; INH,ETH; INH,PZA; PAS,INH,OFX,CIP,MFX,LFX; SM; SM,EMB; SM,EMB,RIF,OFX,CIP,MFX,LFX; SM,INH; SM,INH,EMB; SM,INH,ETH;  
426 SM,PZA,ETH,RIF. Abbreviations: IQR, interquartile range; *Mtb*, *Mycobacterium tuberculosis*; MDR, multi-drug-resistant; pre-XDR/XDR, pre-/ extensively-drug-  
427 resistant; WGS, whole-genome sequencing; SM, streptomycin; PAS, para-aminosalicylic-acid; INH, isoniazid; PZA, pyrazinamide, CS, cycloserine; ETH,  
428 ethionamide; EMB, ethambutol; RIF, rifampicin; OFX, ofloxacin; CIP, ciprofloxacin; MFX moxifloxacin; LFX, levofloxacin.

429

430

**Table 2: Drug resistance results from whole-genome sequencing and local testing by diagnosis concordance and consequences for treatment.**

	Drug resistance categories based on:		Diagnosis method:			
	Diagnosis with WGS	Diagnosis at sites	Xpert MTB/RIF <sup>+</sup>	Culture	LPA	Combination of tests
<b>Concordant diagnosis</b>						
<b>Total: 452 (100%)</b>			<b>242 (100%)</b>	<b>195 (100%)</b>	<b>60 (100%)</b>	<b>102 (100%)</b>
293 (65%)	Pan-susceptible	Pan-susceptible	196 (81%)	139 (71%)	49 (82%)	53 (52%)
5 (1%)	Monoresistance: 3 INH 2 RIF	Monoresistance: 3 INH 2 RIF	0 (0%)	4 (2%)	1 (1.67%)	0 (0%)
138 (31%)	MDR	MDR	45 (18.6%)	44 (23%)	8 (13%)	44 (43%)
9 (2%)	pre-XDR/XDR	pre-XDR/XDR	1 (<1%)	1 (<1%)	2 (3%)	5 (5%)
7 (2%)	Others: 7 SM.	Others: 7 SM	0 (0%)	7 (4%)	0 (0%)	0 (0%)
<b>Discordant diagnosis</b>						
<b>Total: 130 (100%)</b>			<b>35 (100%)</b>	<b>55 (100%)</b>	<b>9 (100%)</b>	<b>46 (100%)</b>
<b>Potentially leading to under-treatment</b>						
<b>Total: 35 (100%)</b>			<b>17 (100%)</b>	<b>12 (100%)</b>	<b>1 (100%)</b>	<b>5 (100%)</b>
0 (0%)	Pan-susceptible	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)
3 (9%)	Monoresistance: 3 INH	3 Pan-susceptible	2 (12%)	1 (8%)	0 (0%)	0 (0%)
5 (14%)	MDR	3 Pan-susceptible 1 RIF 1 SM;EMB	2 (12%)	1 (8%)	1 (100%)	1 (20%)
15 (43%)	pre-XDR/XDR	MDR	5 (29%)	6 (50%)	0 (0%)	4 (80%)
12 (34%)	Others: 10 INH;ETH 1 SM;INH;ETH 1 SM;INH	Pan-susceptible Pan-susceptible Pan-susceptible	8 (47%)	4 (33%)	0 (0%)	0 (0%)
<b>Potentially leading to over-treatment</b>						
<b>Total: 31 (100%)</b>			<b>3 (100%)</b>	<b>12 (100%)</b>	<b>2 (100%)</b>	<b>14 (50%)</b>
23 (74%)	Pan-susceptible	1 INH 18 MDR 4 RIF	3 (100%)	9 (75%)	2 (100%)	9 (64%)
2 (6%)	Monoresistance: 2 INH	MDR	0 (0%)	2 (16.67%)	0 (0%)	0 (0%)

3 (10%)	MDR	pre-XDR/XDR	0 (0%)	0 (0%)	0 (0%)	3 (21%)
0 (0%)	pre-XDR/XDR	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)
3 (10%)	Others: 1 INH;PZA 1 SM;INH;EMB 1 INH;ETH	MDR MDR MDR	0 (0%)	1 (8%)	0 (0%)	2 (14%)
<b>Other discordance in diagnosis</b>						
<b>Total: 64 (100%)</b>			<b>15 (100%)</b>	<b>31 (100%)</b>	<b>6 (100%)</b>	<b>27 (100%)</b>
23 (36%)	Pan-susceptible	20 EMB 1 Monoresistance* 1 SM	2 (13%)	20 (65%)	0 (0%)	1 (4%)
25 (39%)	Monoresistance: 20 RIF 2 PZA 1 EMB	MDR Pan-susceptible Pan-susceptible	6 (40%)	1 (3%)	1 (17%)	20 (74%)
0 (0%)	MDR	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)
0 (0%)	pre-XDR/XDR	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)
16 (25%)	Others: 5 ETH 1 CS. 1 SM. 3 INH;ETH 1 SM;EMB 1 SM;EMB;RIF;OFX;CIP;MFX;LFX 1 SM. 1 PAS;INH;OFX;CIP;MFX;LFX 1 SM;PZA;ETH;RIF 1 EMB;RIF	Pan-susceptible Pan-susceptible SM;EMB INH SM MDR Pan-susceptible INH MDR MDR	7 (47%)	10 (32%)		6 (22%)

432

433 Abbreviations: vs, versus; WGS, whole-genome sequencing; *Mtb*, Mycobacterium tuberculosis; DST, drug susceptibility test; LPA, line probe assay; MDR,  
434 multi-drug-resistant; pre-XDR/XDR, pre-/extensively drug-resistant; WHO, World Health Organization; SM, streptomycin; PAS, para-aminosalicylic-acid; INH,  
435 isoniazid; PZA, pyrazinamide; CS, cycloserine; ETH, ethionamide; EMB, ethambutol; RIF rifampicin; OFX, ofloxacin; CIP, ciprofloxacin; MFX moxifloxacin; LFX,  
436 levofloxacin. \*exact Monoresistance is not known; \*RIF resistance diagnosed with Xpert MTB/RIF was classified as MDR.

437

438

439




440 **Table 3: Mortality by concordance of local diagnosis and whole-genome sequencing.**

	Total	Concordant with diagnosis at sites	Discordant with diagnosis at sites			
			Any discordance	Potentially leading to under-treatment	Potentially leading to over-treatment	Other discordance
<b>Resistance based on WGS:</b>	63/530 (12%)	44/409 (11%)	19/121 (16%)	8/30 (27%)	1/28 (4%)	10/63 (16%)
Pan-susceptible	18/310 (6%)	16/267 (6%)	2/43 (5%)	0/0	0/20 (0%)	2/23 (9%)
Any resistance	45/220 (20%)	28/142 (20%)	17/78 (22%)	8/30 (27%)	1/8 (12%)	8/40 (20%)
<b>Mono-resistance:</b>	6/32 (19%)	2/4 (50%)	4/28 (14%)	0/1 (0%)	0/2 (0%)	4/25 (16%)
INH	1/6 (17%)	1/3 (33%)	0/3 (0%)	0/1 (0%)	0/2 (0%)	0/0
PZA	1/2 (50%)	0/0	1/2 (50%)	0/0	0/0	1/2 (50%)
EMB	0/1 (0%)	0/0	0/1 (0%)	0/0	0/0	0/1 (0%)
RIF	4/23 (17%)	1/1 (100%)	3/22 (14%)	0/0	0/0	3/22 (14%)
<b>Poly-resistance:</b>	39/188 (21%)	26/138 (19%)	13/50 (26%)	8/29 (28%)	1/6 (17%)	4/15 (27%)
MDR	24/131 (18%)	23/123 (19%)	1/8 (12%)	1/5 (20%)	0/3 (0%)	0/0
pre-XDR/XDR	9/23 (39%)	2/8 (25%)	7/15 (47%)	7/15 (47%)	0/0	0/0
Others	6/34 (18%)	1/7 (14%)	5/27 (19%)	0/9 (0%)	1/3 (33%)	4/15 (27%)

441

442 Analysis based on 530 patients with complete data. The estimated mortality is calculated by comparing the deaths compared to the total of the category.  
 443 Abbreviations: WGS, whole-genome sequencing; MDR, multi-drug-resistant; pre-XDR/XDR, pre-/extensively drug-resistant; Others: CS; EMB,RIF; ETH;  
 444 INH,ETH; INH,PZA; PAS,INH,OFX,CIP,MFX,LFX; SM; SM,EMB; SM,EMB,RIF,OFX,CIP,MFX,LFX; SM,INH; SM,INH,EMB; SM,INH,ETH; SM,PZA,ETH,RIF;  
 445 SM, streptomycin; PAS, para-aminosalicylic-acid; INH, isoniazid; PZA, pyrazinamide, CS cycloserine; ETH, ethionamide; EMB, ethambutol; RIF, rifampicin;  
 446 OFX, ofloxacin; CIP, ciprofloxacin; MFX, moxifloxacin; LFX, levofloxacin.

447



448


449 **Figure 1. Distribution of diagnosed drug resistance between whole-genome sequencing and**

450 **local DST.** The categories include pan-susceptible TB, monoresistant TB (any monoresistance), MDR-

451 TB, pre-XDR/XDR-TB, any INH-resistant TB, any RIF-resistant TB. Abbreviations: WGS, whole-

452 genome sequencing; DST, drug susceptibility testing; MDR, multi-drug-resistant; pre-XDR/XDR, pre-


453 /extensively drug-resistant; INH, isoniazid; RIF rifampicin.



454

455 **Figure 2. Mortality according to drug resistance, concordance of diagnosis, and treatment**  
456 **adequacy (according to WHO guidelines, see also supplementary tables 1 and 2).** Error bars are  
457 standard errors. Analysis based on 530 patients with complete data. The estimated mortality is  
458 calculated by comparing the deaths compared to the total amount of the category. Abbreviations: WHO,

459 World Health Organization; MDR, multi-drug-resistant; pre-XDR/XDR, pre-extensively and extensively  
460 drug-resistant.



461

462 **Figure 3. Results from four logistic regression models (adjusted for sex, age, HIV status, history of TB, sputum microscopy, and TB lineage) to**  
 463 **assess 1) the impact of any drug resistance on mortality, 2) the impact of drug resistance categories on mortality, 3) the impact of diagnosis**  
 464 **discordance on mortality, 4) the impact of treatment adequacy (according to WHO guidelines) on mortality.** Abbreviations: OR, odds ratio; CI, confidence  
 465 interval; N, number; *Mtb*, *Mycobacterium tuberculosis*; WHO, world health organisation; MDR, multi-drug-resistant; pre-XDR/XDR, pre-extensively and  
 466 extensively drug-resistant.